Mayo Clinic
This study evaluates the impact of immunotherapy on balance in patients receiving immunotherapy as part of their standard of care.
Inclusion Criteria: * At least 18 years of age at screening * Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab) Exclusion Criteria: * Concurrent chemotherapy
Non-interventional study